Affordable inactivated poliovirus vaccine: strategies and progress.

After polio eradication is achieved, the use of live-attenuated oral poliovirus vaccine (OPV) must be discontinued because of the inherent risk of the Sabin strains to revert to neurovirulence and reacquire greater transmissibility that could potentially result in the reestablishment of polio transmission. In 2008, the World Health Assembly mandated that the World Health Organization establish a strategy for developing more-affordable inactivated poliovirus vaccine (IPV) options for low-income countries. In 2012, the Strategic Advisory Group of Experts (SAGE) on Immunization recommended universal IPV introduction as a risk-mitigation strategy before the phased cessation of OPV (starting with Sabin type 2) and emphasized the need for affordable IPV options. In 2013, SAGE reiterated the importance of attaining the long-term target price of IPV at approximately $0.5 per immunizing dose and encouraged accelerated efforts to develop lower-cost IPV options. This article outlines the 4-pronged approach that is being pursued to develop affordable options and provides an update on the current status and plans to make IPV affordable for developing-country use.

[1]  M. Bonnet,et al.  Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. , 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[2]  W. Bakker,et al.  Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains , 2011, Expert review of vaccines.

[3]  F. Ansaldi,et al.  Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement , 2011, Expert opinion on biological therapy.

[4]  T. Cherian,et al.  Immune response of infants to inactivated poliovirus vaccine injected intradermally. , 1992, Vaccine.

[5]  R. Sutter,et al.  Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial , 2010, The Lancet.

[6]  R. Sutter,et al.  Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. , 2010, The Journal of infectious diseases.

[7]  M. Pallansch,et al.  Vaccine-derived polioviruses and the endgame strategy for global polio eradication. , 2005, Annual review of microbiology.

[8]  M. Pallansch,et al.  Fractional doses of inactivated poliovirus vaccine in Oman. , 2010, The New England journal of medicine.

[9]  M. Pallansch,et al.  Poliovirus vaccination options for achieving eradication and securing the endgame. , 2013, Current opinion in virology.

[10]  B. Aylward,et al.  The polio endgame. , 2011, The New England journal of medicine.

[11]  Mark R. Prausnitz,et al.  Dissolving Polymer Microneedle Patches for Influenza Vaccination , 2010, Nature Medicine.

[12]  T. Cherian,et al.  Immune response to intradermally injected inactivated poliovirus vaccine , 1991, The Lancet.

[13]  Kwok-Hung Chan,et al.  Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. , 2012, Vaccine.

[14]  K. Chumakov,et al.  1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. , 2006, The Journal of infectious diseases.

[15]  R. Sutter,et al.  Priming after a fractional dose of inactivated poliovirus vaccine. , 2013, The New England journal of medicine.

[16]  B. Simizu,et al.  Development of inactivated poliovirus vaccine derived from Sabin strains. , 2006, Biologicals : journal of the International Association of Biological Standardization.

[17]  T. Wu,et al.  Emerging human papillomavirus vaccines , 2012, Expert opinion on emerging drugs.

[18]  R. Johnston,et al.  Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. , 2010, Vaccine.

[19]  K. Chumakov,et al.  New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Prausnitz,et al.  Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. , 2013, Vaccine.

[21]  Yanwen Liang,et al.  CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. , 2009, Vaccine.

[22]  R. Coler,et al.  Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. , 2011, Vaccine.

[23]  Salk Je.  STUDIES in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. , 1953, Cyprus medical journal.

[24]  T. Cherian,et al.  Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. , 1998, Vaccine.

[25]  M. Prausnitz,et al.  Measles vaccination using a microneedle patch. , 2013, Vaccine.

[26]  T. Vedvick,et al.  Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. , 2013, Vaccine.

[27]  P. van Damme,et al.  Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. , 2009, Vaccine.

[28]  K. To,et al.  Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. , 2012, Vaccine.

[29]  M. Greenberg.  LIVE POLIOVIRUS VACCINES , 1960 .

[30]  Who Publication.  Polio vaccines and polio immunization in the pre-eradication era: WHO position paper--recommendations. , 2010, Vaccine.

[31]  W. Bakker,et al.  Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. , 2011, Vaccine.

[32]  J. Salk.  Recent studies on immunization against poliomyelitis. , 1953, Pediatrics.